[{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"MAbSilico solutions","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Nivolumab","moa":"T-lymphocytes","graph1":"Oncology","graph2":"Phase II","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ OSE Immunotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"OSE Immunotherapeutics SA \/ OSE Immunotherapeutics"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Servier","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"OSE-127","moa":"IL-7R","graph1":"Immunology","graph2":"Phase II","graph3":"OSE Immunotherapeutics SA","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Servier","highestDevelopmentStatusID":"8","companyTruncated":"OSE Immunotherapeutics SA \/ Servier"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Tedopi","moa":"T cell","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immunotherapeutics SA \/ Not Applicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Peptide vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immunotherapeutics SA \/ Not Applicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Anti-CLEC-1 monoclonal antibody","moa":"CLEC-1","graph1":"Oncology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immunotherapeutics SA \/ Not Applicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"BiCKI-IL-7","moa":"PD-L1","graph1":"Oncology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immunotherapeutics SA \/ Not Applicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Nantes Metropole","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"Covepit","moa":"SARS-CoV-2 spike protein inhibitor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Nantes Metropole","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immunotherapeutics SA \/ Nantes Metropole"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Tedopi","moa":"Killer T-Cell","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immunotherapeutics SA \/ Not Applicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"CoVepiT","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immunotherapeutics SA \/ Not Applicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Tedopi","moa":"Killer T-Cell","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immunotherapeutics SA \/ Not Applicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"FR104","moa":"CD28","graph1":"Immunology","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics SA \/ Not Applicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"OSE-172","moa":"Checkpoint","graph1":"Oncology","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics SA \/ Not Applicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"OSE-230","moa":"ChemR23","graph1":"Immunology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immunotherapeutics SA \/ Not Applicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"CoVepiT","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics SA \/ Not Applicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"CoVepiT","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Bpifrance","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics SA \/ Bpifrance"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"Tedopi","moa":"Killer T-Cell","graph1":"Oncology","graph2":"Undisclosed","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ European Investment Bank","highestDevelopmentStatusID":"1","companyTruncated":"OSE Immunotherapeutics SA \/ European Investment Bank"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Arcagy Gineco","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"Immune checkpoint","graph1":"Oncology","graph2":"Phase II","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Arcagy Gineco","highestDevelopmentStatusID":"8","companyTruncated":"OSE Immunotherapeutics SA \/ Arcagy Gineco"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"CoVepiT","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics SA \/ Not Applicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"FR104","moa":"CD28","graph1":"Immunology","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0.39000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.39000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"OSE Immunotherapeutics SA \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics SA \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"OSE-172","moa":"CD47","graph1":"Oncology","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Boehringer Ingelheim","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics SA \/ Boehringer Ingelheim"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"CoVepiT","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics SA \/ Not Applicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Cenexi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"CoVepiT","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ OSE Immunotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics SA \/ OSE Immunotherapeutics"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Financing","leadProduct":"Tedopi","moa":"CTLs","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ European Investment Bank","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immunotherapeutics SA \/ European Investment Bank"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Tedopi","moa":"CTLs","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immunotherapeutics SA \/ Not Applicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"OSE-172","moa":"CD47","graph1":"Oncology","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OSE Immunotherapeutics SA \/ OSE Immunotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics SA \/ OSE Immunotherapeutics"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Tedopi","moa":"CTLs","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immunotherapeutics SA \/ Not Applicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"OSE-279","moa":"PD-1","graph1":"Oncology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immunotherapeutics SA \/ Not Applicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"CLRs","graph1":"Oncology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immunotherapeutics SA \/ Not Applicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"Immune checkpoint","graph1":"Oncology","graph2":"Phase II","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OSE Immunotherapeutics SA \/ Not Applicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"CoVepiT","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics SA \/ Not Applicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"OSE-127","moa":"Il-7 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immunotherapeutics SA \/ Not Applicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"OSE-279","moa":"Programmed death receptor-1 \/ Interleukin 7 stimulator","graph1":"Oncology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immunotherapeutics SA \/ Not Applicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"CoVepiT","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics SA \/ Not Applicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"OSE-172","moa":"SIRP alpha","graph1":"Oncology","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":1.3500000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.3500000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"OSE Immunotherapeutics SA \/ Boehringer Ingelheim","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics SA \/ Boehringer Ingelheim"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"FR104","moa":"CD28","graph1":"Immunology","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"OSE Immunotherapeutics SA \/ OSE Immunotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics SA \/ OSE Immunotherapeutics"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"OSE2101","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immunotherapeutics SA \/ Not Applicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"OSE2101","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immunotherapeutics SA \/ Not Applicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"OSE2101","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Bpifrance","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immunotherapeutics SA \/ Bpifrance"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"BI 770371","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics SA \/ Not Applicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Large molecule","year":"2024","type":"Partnership","leadProduct":"OSE-230","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0.70999999999999996,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.70999999999999996,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immunotherapeutics SA \/ AbbVie Inc"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"OSE2101","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Bpifrance","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immunotherapeutics SA \/ Bpifrance"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"OSE-230","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0.70999999999999996,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.70999999999999996,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immunotherapeutics SA \/ AbbVie Inc"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Nantes University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"FR104","moa":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Nantes University Hospital","highestDevelopmentStatusID":"7","companyTruncated":"OSE Immunotherapeutics SA \/ Nantes University Hospital"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"CAR-T Based Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immunotherapeutics SA \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"BI 754091","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Boehringer Ingelheim GmBH","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics SA \/ Boehringer Ingelheim GmBH"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"BI 770371","moa":"","graph1":"Technology","graph2":"Approved","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ OSE Immunotherapeutics SA","highestDevelopmentStatusID":"12","companyTruncated":"OSE Immunotherapeutics SA \/ OSE Immunotherapeutics SA"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Lusvertikimab","moa":"","graph1":"Technology","graph2":"Approved","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"OSE Immunotherapeutics SA \/ Not Applicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"OSE2101","moa":"","graph1":"Technology","graph2":"Approved","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"OSE Immunotherapeutics SA \/ Not Applicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Lusvertikimab","moa":"","graph1":"Technology","graph2":"Approved","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"OSE Immunotherapeutics SA \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by OSE Immunotherapeutics SA

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : OSE-127 (lusvertikimab) is a humanized monoclonal antibody targeting the IL-7R, currently in mid-stage trials for ulcerative colitis. It shows promising efficacy and a favorable safety profile.

                          Brand Name : OSE-127

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          November 04, 2024

                          Lead Product(s) : Lusvertikimab

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Tedopi (OSE2101) neoepitope-based cancer vaccine. It is being evaluated in the clinical trial for the treatment of HLA-A2 positive non-small cell lung cancer.

                          Brand Name : Tedopi

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          September 10, 2024

                          Lead Product(s) : OSE2101

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : OSE-127 (lusvertikimab) is a humanized monoclonal antibody targeting the IL-7 receptor, currently in Phase 2 trials for ulcerative colitis. It shows promising efficacy and a favorable safety profile.

                          Brand Name : OSE-127

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          July 24, 2024

                          Lead Product(s) : Lusvertikimab

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : BI 770371 is a novel anti-SIRPα monoclonal antibody (mAb) targeting both V1 and V2 SIRPα. It is currently in clinical studies for various immuno-oncology diseases like NSCLC, HNSCC & melanoma.

                          Brand Name : BI 770371

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          July 03, 2024

                          Lead Product(s) : BI 770371,Ezabenlimab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Boehringer Ingelheim GmbH

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : This new agreement is based on the initial multi-year research collaboration between MSK and OSE Immunotherapeutics to explore the preclinical potential against IL-7R Acute Lymphoblastic Leukemia.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          June 24, 2024

                          Lead Product(s) : CAR-T Based Therapy

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Memorial Sloan Kettering Cancer Center

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          06

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : FR104 is a pegylated monoclonal antibody fragment that bind to and blocks CD28-mediated effector-T cell co-stimulation, that acts as a natural brake on the body’s immune responses for transplantation.

                          Brand Name : VEL-101

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          June 05, 2024

                          Lead Product(s) : FR104

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Nantes University Hospital

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The collaboration aims to support the advancement of company's investigational product BI 765063, an anti-SIRPα immuno-oncology compound for the treatment of neoplasms.

                          Brand Name : BI 765063

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          May 22, 2024

                          Lead Product(s) : BI 765063,BI 754091

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Boehringer Ingelheim GmbH

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          08

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Under the licensing agreement, AbbVie to develop OSE-230, a monoclonal antibody designed to resolve chronic and severe inflammation, currently in the pre-clinical development stage.

                          Brand Name : OSE-230

                          Molecule Type : Large molecule

                          Upfront Cash : $48.0 million

                          April 16, 2024

                          Lead Product(s) : OSE-230

                          Therapeutic Area : Immunology

                          Highest Development Status : Preclinical

                          Sponsor : AbbVie Inc

                          Deal Size : $713.0 million

                          Deal Type : Licensing Agreement

                          blank

                          09

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Funding will support the clinical development of Tedop (OSE2101), a neoepitope-based cancer vaccine, being evaluated for HLA-A2 positive non-small cell lung cancer in clinical trials.

                          Brand Name : Tedopi

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          April 10, 2024

                          Lead Product(s) : OSE2101

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Bpifrance

                          Deal Size : $9.0 million

                          Deal Type : Funding

                          blank

                          10

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The partnership aims to focus on the development of OSE-230, which is an agonist antibody against ChemR23. It is being evaluated in the preclinical trial studies for chronic and severe inflammation.

                          Brand Name : OSE-230

                          Molecule Type : Large molecule

                          Upfront Cash : $48.0 million

                          February 28, 2024

                          Lead Product(s) : OSE-230

                          Therapeutic Area : Immunology

                          Highest Development Status : Preclinical

                          Sponsor : AbbVie Inc

                          Deal Size : $713.0 million

                          Deal Type : Partnership

                          blank